ADC Landscape
Daiichi Sankyo
HER2 · HER2+ & HER2-low breast, gastric, lung
ApprovedAntibody–Drug Conjugates
Target
HER2
Payload
Deruxtecan (DXd)
Payload class
Topo-I inhibitor
Linker
Cleavable tetrapeptide (GGFG)
Indication
HER2+ & HER2-low breast, gastric, lung
Phase
Approved
Partner
AstraZeneca
Overview
The drug that redefined the field. High drug-to-antibody ratio (~8), a membrane-permeable payload enabling bystander killing, and efficacy even in HER2-LOW tumors — expanding the addressable population enormously. Set off the modern ADC gold rush.
Technology
Daiichi Sankyo works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Roche / Genentech
HER2
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.